Catalyst Funds Management’s C4 Therapeutics CCCC Stock Holding History

Catalyst Funds Management’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25,740	Closed	-$67.7K	–	692
2026 Q1	$67.7K	Sell	25,740 -16,760	-39%	-$39.5K	0.01%	519
2025 Q4	$81.2K	Hold	42,500	–	–	0.02%	318
2025 Q3	$94.3K	Buy	42,500 +14,200	+50%	+$34.1K	0.01%	460
2025 Q2	$40.5K	Buy	+28,300	New	+$41.2K	0.01%	386
2024 Q3	–	Sell	-23,228	Closed	-$107K	–	1333
2024 Q2	$107K	Buy	+23,228	New	+$139K	0.03%	275

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Catalyst Funds Management's CCCC Position: Q2 2026 in Review

Catalyst Funds Management sold out of C4 Therapeutics (CCCC) in Q2 2026, closing a stake of 25,740 shares — an estimated $67.7K sold.

Catalyst Funds Management first reported a position in CCCC in Q2 2024 and held it in 5 quarters. The position peaked at $107K in Q2 2024. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Catalyst Funds Management reported no remaining C4 Therapeutics position as of Q2 2026 after selling out during the quarter.
Catalyst Funds Management sold 25,740 C4 Therapeutics shares in Q2 2026, an estimated $67.7K.
Catalyst Funds Management first reported a position in C4 Therapeutics in Q2 2024 and held it in 5 quarters.
Catalyst Funds Management's C4 Therapeutics position peaked at $107K in Q2 2024.
148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.